Adverse Cardiovascular Events During Treatment with Pioglitazone and Rosiglitazone: Population Based Cohort Study

Overview

Journal BMJ

Specialty General Medicine

Date 2009 Aug 20

PMID 19690342

Citations 65

Authors

David N Juurlink

Tara Gomes

Lorraine L Lipscombe

Peter C Austin

Janet E Hux

Muhammad M Mamdani

Affiliations

Soon will be listed here.

Abstract

Objective: To compare the risk of acute myocardial infarction, heart failure, and death in patients with type 2 diabetes treated with rosiglitazone and pioglitazone.

Design: Retrospective cohort study.

Setting: Ontario, Canada.

Participants: Outpatients aged 66 years and older who were started on rosiglitazone or pioglitazone between 1 April 2002 and 31 March 2008.

Main Outcome Measure: Composite of death or hospital admission for either acute myocardial infarction or heart failure. In a secondary analysis, each outcome was also examined individually.

Results: 39 736 patients who started on either pioglitazone or rosiglitazone were identified. During the six year study period, the composite outcome was reached in 895 (5.3%) of patients taking pioglitazone and 1563 (6.9%) of patients taking rosiglitazone. After extensive adjustment for demographic and clinical factors and drug doses, pioglitazone treated patients had a lower risk of developing the primary outcome than did patients treated with rosiglitazone (adjusted hazard ratio 0.83, 95% confidence interval 0.76 to 0.90). Secondary analyses revealed a lower risk of death (adjusted hazard ratio 0.86, 0.75 to 0.98) and heart failure (0.77, 0.69 to 0.87) with pioglitazone but no significant difference in the risk of acute myocardial infarction (0.95, 0.81 to 1.11). One additional composite outcome would be predicted to occur annually for every 93 patients treated with rosiglitazone rather than pioglitazone.

Conclusions: Among older patients with diabetes, pioglitazone is associated with a significantly lower risk of heart failure and death than is rosiglitazone. Given that rosiglitazone lacks a distinct clinical advantage over pioglitazone, continued use of rosiglitazone may not be justified.

Citing Articles

Understanding Diabetic Cardiomyopathy: Insulin Resistance and Beyond.

Binu A, Kapoor N Heart Int. 2025; 18(2):7-13.

PMID: 39885933 PMC: 11781369. DOI: 10.17925/HI.2024.18.2.2.

Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.

Portincasa P, Khalil M, Mahdi L, Perniola V, Idone V, Graziani A Int J Mol Sci. 2024; 25(11).

PMID: 38891828 PMC: 11172019. DOI: 10.3390/ijms25115640.

The Effect of Thiazolidinediones in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Abdalla M, Shah N, Deshmukh H, Sahebkar A, Ostlundh L, Al-Rifai R Adv Ther. 2024; 41(6):2168-2195.

PMID: 38683294 DOI: 10.1007/s12325-024-02848-3.

Evaluating the Efficacy of ChatGPT in Navigating the Spanish Medical Residency Entrance Examination (MIR): Promising Horizons for AI in Clinical Medicine.

Guillen-Grima F, Guillen-Aguinaga S, Guillen-Aguinaga L, Alas-Brun R, Onambele L, Ortega W Clin Pract. 2023; 13(6):1460-1487.

PMID: 37987431 PMC: 10660543. DOI: 10.3390/clinpract13060130.

Suberosin Alleviates Thiazolidinedione-Induced Cardiomyopathy in Diabetic Rats by Inhibiting Ferroptosis via Modulation of ACSL4-LPCAT3 and PI3K-AKT Signaling Pathways.

Iqbal S, Jabeen F, Kahwa I, Omara T Cardiovasc Toxicol. 2023; 23(9-10):295-304.

PMID: 37676618 DOI: 10.1007/s12012-023-09804-7.

References

Wild S, Roglic G, Green A, Sicree R, King H . Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5):1047-53. DOI: 10.2337/diacare.27.5.1047. View

Stafylas P, Sarafidis P, Lasaridis A . The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int J Cardiol. 2008; 131(3):298-304. DOI: 10.1016/j.ijcard.2008.06.005. View

Karter A, Ahmed A, Liu J, Moffet H, Parker M . Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med. 2005; 22(8):986-93. PMC: 3557913. DOI: 10.1111/j.1464-5491.2005.01704.x. View

Lipscombe L, Gomes T, Levesque L, Hux J, Juurlink D, Alter D . Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007; 298(22):2634-43. DOI: 10.1001/jama.298.22.2634. View

Margolis D, Hoffstad O, Strom B . Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf. 2008; 17(8):753-9. PMC: 2635115. DOI: 10.1002/pds.1630. View

Mamdani M, Rochon P, Juurlink D, Anderson G, Kopp A, Naglie G . Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 2003; 163(4):481-6. DOI: 10.1001/archinte.163.4.481. View

Jamieson A, Abousleiman Y . Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc. 2004; 79(4):571. DOI: 10.4065/79.4.571. View

Young P, Buckle D, Cantello B, Chapman H, Clapham J, Coyle P . Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther. 1998; 284(2):751-9. View

Psaty B, Furberg C . The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med. 2007; 357(1):67-9. DOI: 10.1056/NEJMe078116. View

10.

Zinn A, Felson S, Fisher E, Schwartzbard A . Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clin Cardiol. 2008; 31(9):397-403. PMC: 6653757. DOI: 10.1002/clc.20312. View

11.

Goldberg R, Kendall D, Deeg M, Buse J, Zagar A, Pinaire J . A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005; 28(7):1547-54. DOI: 10.2337/diacare.28.7.1547. View

12.

Austin P . Absolute risk reductions, relative risks, relative risk reductions, and numbers needed to treat can be obtained from a logistic regression model. J Clin Epidemiol. 2009; 63(1):2-6. DOI: 10.1016/j.jclinepi.2008.11.004. View

13.

Juurlink D, Mamdani M, Lee D, Kopp A, Austin P, Laupacis A . Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351(6):543-51. DOI: 10.1056/NEJMoa040135. View

14.

Pfutzner A, Marx N, Lubben G, Langenfeld M, Walcher D, Konrad T . Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005; 45(12):1925-31. DOI: 10.1016/j.jacc.2005.03.041. View

15.

Gerrits C, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S . A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf. 2007; 16(10):1065-71. DOI: 10.1002/pds.1470. View

16.

Rosen C . The rosiglitazone story--lessons from an FDA Advisory Committee meeting. N Engl J Med. 2007; 357(9):844-6. DOI: 10.1056/NEJMp078167. View

17.

Haffner S, DAgostino Jr R, Mykkanen L, Tracy R, Howard B, Rewers M . Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 1999; 22(4):562-8. DOI: 10.2337/diacare.22.4.562. View

18.

Austin P, Daly P, Tu J . A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J. 2002; 144(2):290-6. DOI: 10.1067/mhj.2002.123839. View

19.

Home P, Pocock S, Beck-Nielsen H, Gomis R, Hanefeld M, Jones N . Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med. 2007; 357(1):28-38. DOI: 10.1056/NEJMoa073394. View

20.

Dormandy J, Charbonnel B, Eckland D, Erdmann E, Massi-Benedetti M, Moules I . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366(9493):1279-89. DOI: 10.1016/S0140-6736(05)67528-9. View